inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiski līdzekļi - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
rilexine 75 mg tabletes
virbac s.a., francija - cefaleksīns monohidrāts - tabletes - 75 mg - kaķi; suņi
rilexine 300 mg tabletes
virbac s.a., francija - cefaleksīns monohidrāts - tabletes - 300 mg - suņi
zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiski līdzekļi - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatas audzējiem, kastrācija-izturīgs - antineoplastiski līdzekļi - treatment of adult patients with prostate cancer.
spasmium comp. 500 mg/ml + 4 mg/ml
richter pharma ag, austrija - metamizols nātrija monohidrāta, hyoscini butylbromidum - šķīdums injekcijām - cūkas; liellopi; suņi; zirgi
kefamast dry cow suspensija ievadīšanai tesmenī
bimeda animal health limited, Īrija - cefaleksīns monohidrāts, dihidrostreptomicīns sulfāts - suspensija ievadīšanai tesmenī - cietstāvošas govis
fotivda
recordati netherlands b.v. - tivozanibs - karcinoma, nieru šūna - antineoplastiski līdzekļi - fotivda ir norādīts pirmās rindas ārstēšanai pieaugušiem pacientiem ar nieru papildu šūnu karcinoma (rsp) un pieaugušiem pacientiem, kas ir vegfr un mtor ceļš inhibitors-naiva pēc slimības progresēšanu pēc vienas iepriekšējas apstrādes ar cytokine terapija uzlabotas rcc. Ārstēšana papildu nieru šūnu karcinomu.
rilexine 600 mg tabletes
virbac s.a., francija - cefaleksīns monohidrāts - tabletes - 600 mg - suņi
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imūnsupresanti - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ir norādīts ārstēšanai pieaugušiem pacientiem ar iepriekš neārstētiem multiplā mieloma, kas nav tiesīgi transplantātu. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).